Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers

Abstract

<p>Supplemental Figure S1. Protein level changes induced by CUDC-907, panobinostat, or pictilisib in MYC-altered DLBCL cell lines; Supplemental Figure S2. CUDC-907 induced changes in WSU DLCL2 cells; Supplemental Figure S3. CUDC-907 changes the mRNA expression pattern of a subset of MYC target genes; Supplemental Figure S4. CUDC-907 does not induce significant body weight loss or obvious toxicity in human DLBCL cell line-derived xenograft models or Eμ-Myc transgenic tumor mouse syngeneic models of B-cell lymphoma; Supplemental Figure S5. CUDC-907 decreases MYC protein levels in cell line-derived Burkitt lymphoma xenograft tumors; Supplemental Figure S6. Protein level changes induced by CUDC-907, panobinostat, or pictilisib in MYC-dependent NMC cell lines; Supplemental Figure S7. CUDC-907 does not induce significant body weight loss or obvious toxicity in human NMC cell line-derived xenograft models; Supplemental Figure S8. Antitumor activity of CUDC-907 in human DLBCL cell line Karpas 422-derived xenograft model.</p>